GAITHERSBURG, Md., Oct. 11 /PRNewswire-FirstCall/ -- MedImmune, Inc.
(Nasdaq: MEDI) has been named to Maryland's Technology Fast 50 Program for the
8th year in a row. The Technology Fast 50 is a ranking of the 50 fastest
growing technology companies in the area by Deloitte & Touche LLP. This
year's rankings are based on the percentage of growth in fiscal year revenues
for the five year period of 1999-2003. Wilmer, Cutler, Pickering, Hale and
Dorr is the sponsor for this year's Maryland Technology Fast 50 program and PR
Newswire is the official media partner.
"MedImmune's total revenues surpassed the billion-dollar mark for the
first time in 2003," said Lota S. Zoth, MedImmune's chief financial officer.
"Exciting accomplishments also included receiving regulatory approval for
FluMist(R), the first innovation in influenza vaccine technology in more than
50 years, and substantially advancing our development pipeline."
"In today's economy, double-digit percentage revenue growth is an
exceptional accomplishment," said Gary H. Tabach of Deloitte's Technology,
Media Telecommunications Practice and Office Managing Partner for Deloitte's
McLean, Virginia office. "We commend MedImmune for making the commitment to
technology and delivering on the promise of market longevity. We are proud to
once again honor MedImmune as a Deloitte Technology Fast 50 winner."
To qualify for the Technology Fast 50, companies must have had operating
revenues of at least $50,000 in 1999 and $1,000,000 in 2003, must be public or
private companies headquartered in North America, and be a "technology
company" defined as owning proprietary technology that contributes to a
significant portion of the company's operating revenues (using other
companies' technology in a unique way does not qualify); and/or devoting a
significant proportion of revenues to research and development of technology.
Winners of the 19 regional Technology Fast 50 programs in the United
States and Canada are automatically entered in the Deloitte Technology Fast
500 program, which ranks North America's top 500 fastest growing technology
companies. For more information on the Fast 50 or Fast 500 programs, visit
MedImmune strives to provide better medicines to patients, new medical
options for physicians, rewarding careers to employees, and increased value to
shareholders. Dedicated to advancing science and medicine to help people live
better lives, the company is focused on the areas of pediatric infectious
diseases, cancer and inflammatory diseases. With approximately 1,900
employees worldwide, MedImmune is headquartered in Maryland. For more
information, visit the company's website at http://www.medimmune.com.
Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss
Verein, its member firms, and their respective subsidiaries and affiliates.
Deloitte Touche Tohmatsu is an organization of member firms around the world
devoted to excellence in providing professional services and advice, focused
on client service through a global strategy executed locally in nearly 150
countries. With access to the deep intellectual capital of 120,000 people
worldwide, Deloitte delivers services in four professional areas -- audit,
tax, consulting, and financial advisory services -- and serves more than one-
half of the world's largest companies, as well as large national enterprises,
public institutions, locally important clients, and successful, fast-growing
global growth companies. Services are not provided by the Deloitte Touche
Tohmatsu Verein, and for regulatory and other reasons, certain member firms do
not provide services in all four professional areas.
As a Swiss Verein (association), neither Deloitte Touche Tohmatsu nor any
of its member firms has any liability for each other's acts or omissions.
Each of the member firms is a separate and independent legal entity operating
under the names "Deloitte," "Deloitte & Touche," "Deloitte Touche Tohmatsu,"
or other related names.
In the U.S., Deloitte & Touche USA LLP is the member firm of Deloitte
Touche Tohmatsu, and services are provided by the subsidiaries of Deloitte &
Touche USA LLP (Deloitte & Touche LLP, Deloitte Consulting LLP, Deloitte Tax
LLP, and their subsidiaries) and not by Deloitte & Touche USA LLP. The
subsidiaries of the U.S. member firm are among the nation's leading
professional services firms, providing audit, tax, consulting, and financial
advisory services through nearly 30,000 people in more than 80 cities. Known
as employers of choice for innovative human resources programs, they are
dedicated to helping their clients and their people excel. For more
information, please visit the U.S. member firm's website at
This announcement may contain, in addition to historical information,
certain forward-looking statements that involve risks and uncertainties. Such
statements reflect management's current views and are based on certain
assumptions. Actual results could differ materially from those currently
anticipated as a result of a number of factors, including risks and
uncertainties discussed in the company's filings with the U.S. Securities and
Exchange Commission. The company is developing several products for potential
future marketing. There can be no assurance that such development efforts
will succeed, that such products will receive required regulatory clearance or
that, even if such regulatory clearance were received, such products would
ultimately achieve commercial success.
SOURCE MedImmune, Inc.
/CONTACT: Media: Jamie Lacey, +1-301-398-4035, or Investors: Peter Vozzo,
+1-301-398-4358, or John Filler, +1-301-398-4086, all of MedImmune, Inc./
/Web site: http://www.medimmune.com
CO: MedImmune, Inc.; Deloitte & Touche LLP; Wilmer, Cutler, Pickering, Hale
and Dorr; PR Newswire
IN: MTC HEA BIO
-- DCM050 --
3428 10/11/2004 17:22 EDT http://www.prnewswire.com